ClinicalTrials.gg
Not yet recruitingNCT04954027AIAUpdated Oct 23, 2026

Attachment and Prognostic Factor: the Implicit Approach

An observational study in Dependence Addictive, sponsored by Centre Hospitalier Henri Laborit. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Centre Hospitalier Henri Laborit · Observational

How we know

Updated Oct 23, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a prospective longitudinal study aimed at better understanding the determinants of the prognosis of patients with substance dependence.

5 visits are planned during the study :

  • the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online
  • 4 telephone interviews for follow-up by investigator.
02

Conditions studied

  • Dependence Addictive

Browse trials for

Keywords

  • implicit approach
  • post-weaning prognostic factor
03

In context

Behavior, Addictive

522 studies on the registry are indexed under Behavior, Addictive; 125 are open to participants now.

This study's planned enrollment of 200 is above the median of 155 across 107 observational studies indexed under Behavior, Addictive.

Browse Behavior, Addictive studies →

Lead sponsor

Centre Hospitalier Henri Laborit is the lead sponsor of 27 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with a use-related disorder weaning for a substance, supported within the addictology sector of Henri Laborit Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients between 18 and 65 years old
  • Patients with a use-related disorder as defined by DSM5
  • Patients weaning for a substance, supported within the addictology sector of Henri Laborit Hospital
  • Having expressed non-opposition to participating in the study after receiving written information.

Exclusion criteria

Exclusion Criteria:

  • Person who cannot read or write
  • Simultaneous participation in a therapeutic trial involving oxytocin
  • Patients protected by law
  • Patients who do not have French as their native language
  • Patients who, in the opinion of the investigator, are unable to complete the questionnaires
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with a use-related disorder weaning for a substance

    Behavioral: Questionnaires

Interventions

  • BehavioralQuestionnaires

    5 visits are planned during the study : * the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online * 4 telephone interviews for follow-up by investigator

06

What researchers measure

Primary outcomes

  1. Implicit attachment and onsumption

    Assessment of the link between implicit attachment and changes in consumption after a 12-month follow-up

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2027; primary completion for Sep 2029, 24 months later.

Of 46 non-industry observational studies under Behavior, Addictive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 111. This study's planned 24 months is below that.

Counting every sponsor, half of 49 studies reached it within 40 months; a quarter within 20 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: start Sep 2026 → Sep 2027, primary completion Sep 2028 → Sep 2029 and completion Sep 2028 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2021
First posted
Jul 8, 2021
StartEst.
Sep 2027was Sep 2026
Primary completionEst.
Sep 2029was Sep 2028
CompletionEst.
Sep 2029was Sep 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Sep 2027
Oct 23, 2026
Primary completion
Sep 2028→Sep 2029
Oct 23, 2026
Study completion
Sep 2028→Sep 2029
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Start date Sep 2026→Sep 2027
    Primary completion Sep 2028→Sep 2029
    Study completion Sep 2028→Sep 2029
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04954027
Lead sponsor
Centre Hospitalier Henri Laborit
Responsible party
Sponsor
First posted
Jul 8, 2021
Start date
Sep 2027 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Wilfried SERRA, Dr
Contact
wilfried.serra@ch-poitiers.fr
0033 5 16 52 61 18
Wilfried SERRA, Dr
principal investigator · Centre Hospitalier Henri Laborit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion